What better way to start the year then with staying on top of healthcare.  This episode covers the new flu guidelines, a novel mechanism in schizophrenia, and Newly found risk of basal insulin and sulfonylureas. IDSA influenza guidelines- http://bit.ly/2QYLM5Q Novel schizophrenia molecule  SEP-363856 - http://bit.ly/2QaiFr3 What is a PANSS test- http://bit.ly/2GOhCOa New emergent risks with Basal insulin and Sulfonylureas- http://bit.ly/2QXF1kG New flu medication Xofluza (baloxivir marboxil) - http://bit.ly/2EWt9s5

This week I review what's going on with the Valsartan recall, VTE risk reduction in prophylaxis, Increased death in children with antipsychotics, new cannabis therapy, and new use for modafinil. 1. Valsartan recall https://wb.md/2EBred0 FDA warning letter: http://bit.ly/2STOdTF 2. Apixiban Reduction of VTE risk in Cancer Patients: https://wb.md/2rKavvI AVERT Study: http://bit.ly/2CkGGYS 3. Antipyschotics linked to increased mortality in young patients https://wb.md/2CkRg1S Full study: http://bit.ly/2BBV3Xd 4. Cannabis use disorder https://wb.md/2LoZ9q7 Full study for purchase: http://bit.ly/2S8lyub 5. Modafinil for stimulant abuse https://www.medscape.com/viewarticle/906587 Any questions or ideas please contact me at [email protected]

This episode reviews what has happened in the previous week in healthcare. For more information on the topics discussed please see the links provided.

Valsartan recall: https://www.medscape.com/viewarticle/906158

FDA list of recent Mylan lots: https://www.fda.gov/Safety/Recalls/ucm627647.htm?utm_campaign=FDA%20updates%20on%20angiotensin%20II%20receptor%20blocker%20(ARB)%20recalls:%20Mylan%20expands&utm_medium=email&utm_source=Eloqua

This Table will go over "NDMA" levels not NDEA as mentioned. NDEA results will be released at a later date: https://www.fda.gov/Drugs/DrugSafety/ucm622717.htm

Medications other than statins: https://www.medscape.com/viewarticle/905377

Study on the mediteranian diet: https://www.medscape.com/viewarticle/898110

Information on PCSK9 (evolocumab) inhibitor: https://reference.medscape.com/drug/repatha-evolocumab-1000002

Zetia (ezetimibe) information: https://reference.medscape.com/drug/zetia-ezetimibe-342454

Dextenza: https://www.medscape.com/viewarticle/905896

https://reference.medscape.com/drug/dextenza-dexamethasone-ophthalmic-insert-1000162

Niacin Fibrates:

Atezolizumab new indication: https://www.medscape.com/viewarticle/906252

Bladder cancer information: https://emedicine.medscape.com/article/438262-overview

Bevacizumab: https://reference.medscape.com/drug/avastin-bevacizumab-https://reference.medscape.com/drug/avastin-bevacizumab-342257

Paclitaxel: https://reference.medscape.com/drug/taxol-paclitaxel-342187

Carboplatnin: https://reference.medscape.com/drug/paraplatin-carboplatin-342107

IMPOWER150 Trial info: https://www.esmo.org/Oncology-News/ASCO-2018-First-Line-Atezolizumab-Improves-Survival-in-Advanced-NSCLC

Again Thanks for listening! My email in [email protected]

Ever wonder why take a statin? Especially if your young and beautiful other health problems. Take a listen to this podcast and learn why.

This episode goes into some more valsartan recalls, AML drugs and AHA HTN guidelines controversy, and lipid guidelines

1. Valsartan recall 2. Travelers diarrhea 3. AML 4. Supplement contamination 5. Chicago shooting